{"entity":{"id":"nct04980885","kind":"trial","name":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","aka":[],"tldr":"A phase 1/2 trial of AK117 and Azacitidine in acute myeloid leukaemia, run by Akeso, active and no longer recruiting.","summary":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04980885 by Akeso, with 68 participants enrolled, started 2021-08-13 and due to reach its primary completion in 2025-09. Interventions recorded: AK117 and Azacitidine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04980885","url":"https://clinicaltrials.gov/study/NCT04980885"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["ak117","azacitidine"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04980885","phase":"1/2","setting":"A Phase Ib/II Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","sponsor":"Akeso","enrolled":68,"outcomes":[]},"route":"/trials/nct04980885/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/"},{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}